Companies like Noom and Hims have also launched programs to prescribe microdosed GLP-1s, claiming that these smaller doses can reduce metabolic risk, lower inflammatory markers, and even lower the risk of cognitive decline. Evidence of sustained patient use post-shortage: Prescription volume and utilization of compounded semaglutide and tirzepatide have continued to grow despite the end of medication shortages, suggesting that compounders may be leveraging additives or dosage adjustments to justify production
10.1038/sj.jcbfm.9600375 185 YeJ.HuX.WangZ.LiR.GanL.ZhangM.et al (2023)
As Bayside pointed out, a Reddit user complained that Wegovy ads are played incessantly during sporting events and another responded I dont watch sporting events and I have seen this bizarre commercial so many times its becoming part of the fabric of my life very disturbing. Advertising, Bayside argued, was an interesting thing to do when you are trying to control demand to end a drug shortage. Bayside said they also conducted their own channel checks of availability
Like IGF-1 LR3, its become a popular drug among bodybuilders and athletes and is typically injected
NSL literature pointer PMID 1451645 L-Carnitine laboratory index [PMID: 1451645] National Science Labs indexing note for PMID 1451645: review the PubMed methods, models, and limitations before citing
One of the most exciting advancements in our industry is the use of GLP-1 medications, a revolutionary weight loss medication that supports long-term, sustainable results